We are live on ! Find out more
ENTA icon

Enanta Pharmaceuticals
ENTA

179 hedge funds and large institutions have $1.4B invested in Enanta Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 44 funds opening new positions, 65 increasing their positions, 49 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more first-time investments, than exits

New positions opened: 44 | Existing positions closed: 11

33% more funds holding in top 10

Funds holding in top 10: 3 → 4 (+1)

33% more repeat investments, than reductions

Existing positions increased: 65 | Existing positions reduced: 49

27% more capital invested

Capital invested by funds: $1.1B → $1.4B (+$301M)

22% more funds holding

Funds holding: 147 → 179 (+32)

3.51% less ownership

Funds ownership: 95.94% → 92.44% (-3.5%)

88% less call options, than puts

Call options by funds: $2.86M | Put options by funds: $23.5M

Holders
179
Holders Change
+32
Holders Change %
+21.77%
% of All Funds
2.75%
Holding in Top 10
4
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+33.33%
% of All Funds
0.06%
New
44
Increased
65
Reduced
49
Closed
11
Calls
$2.86M
Puts
$23.5M
Net Calls
-$20.6M
Net Calls Change
-$23.5M

Top Buyers

1
Invesco
Invesco
Georgia
+$14.4M
2
DGM
Darwin Global Management
Jersey
+$13M
3
CS
Candriam SCA
Luxembourg
+$12.7M
4
SCM
Soleus Capital Management
Connecticut
+$10.7M
5
FFM
Fairmount Funds Management
Pennsylvania
+$5.53M

Top Sellers

1
AC
Armistice Capital
New York
-$61.2M
2
FCM
Farallon Capital Management
California
-$33.1M
3
KAM
Krensavage Asset Management
New York
-$29.2M
4
Vanguard Group
Vanguard Group
Pennsylvania
-$13.7M
5
BlackRock
BlackRock
New York
-$9.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
BlackRock
1
BlackRock
New York
$260M -$9.7M -123,638 -3%
Vanguard Group
2
Vanguard Group
Pennsylvania
$122M -$13.7M -174,454 -10%
FCM
3
Farallon Capital Management
California
$118M -$33.1M -421,171 -21%
State Street
4
State Street
Massachusetts
$84.3M +$4.31M +54,887 +5%
AC
5
Armistice Capital
New York
$79M -$61.2M -780,000 -42%
Northern Trust
6
Northern Trust
Illinois
$75.7M +$4.17M +53,116 +6%
First Manhattan
7
First Manhattan
New York
$72.5M – – –
Renaissance Technologies
8
Renaissance Technologies
New York
$53.4M -$3.31M -42,185 -6%
Dimensional Fund Advisors
9
Dimensional Fund Advisors
Texas
$45M -$716K -9,128 -1%
KAM
10
Krensavage Asset Management
New York
$42.2M -$29.2M -372,675 -40%
FFM
11
Fairmount Funds Management
Pennsylvania
$29M +$5.53M +70,448 +22%
Geode Capital Management
12
Geode Capital Management
Massachusetts
$25.1M +$174K +2,215 +0.7%
SCM
13
Soleus Capital Management
Connecticut
$23.8M +$10.7M +135,875 +74%
Invesco
14
Invesco
Georgia
$21.7M +$14.4M +183,676 +173%
T. Rowe Price Associates
15
T. Rowe Price Associates
Maryland
$20.5M +$957K +12,194 +5%
Jacobs Levy Equity Management
16
Jacobs Levy Equity Management
New Jersey
$20.2M +$1.28M +16,316 +6%
Bank of New York Mellon
17
Bank of New York Mellon
New York
$14.6M +$951K +12,119 +7%
GIM
18
Granahan Investment Management
Massachusetts
$13.9M +$204K +2,595 +1%
DGM
19
Darwin Global Management
Jersey
$12.4M +$13M +166,190 New
CS
20
Candriam SCA
Luxembourg
$12.1M +$12.7M +161,358 New
Acadian Asset Management
21
Acadian Asset Management
Massachusetts
$9.9M -$8.33M -106,113 -44%
Charles Schwab
22
Charles Schwab
California
$9.67M +$119K +1,517 +1%
Morgan Stanley
23
Morgan Stanley
New York
$9.43M -$2.84M -36,163 -22%
Norges Bank
24
Norges Bank
Norway
$9.3M +$1.13M +14,408 +13%
Principal Financial Group
25
Principal Financial Group
Iowa
$9.14M -$346K -4,409 -3%
1
2 3 4 5

ENTA Hedge Fund Activity: Q4 2021 in Review

179 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Enanta Pharmaceuticals (ENTA) for Q4 2021, worth a combined $1.4B — up 27% from $1.1B a quarter earlier.

Buyers outnumbered sellers: 44 funds opened new ENTA positions and 11 closed out — a net gain of 33 holders — while 65 added to existing stakes and 49 trimmed.

The largest buyer was Invesco, adding an estimated $14.4M. The largest seller was Armistice Capital, cutting an estimated $61.2M.

  • 179 institutional investors held Enanta Pharmaceuticals (ENTA) as of Q4 2021, up from 147 in Q3 2021.
  • Funds reported $1.4B of Enanta Pharmaceuticals stock for Q4 2021, up 27% quarter-over-quarter.
  • 44 funds opened new Enanta Pharmaceuticals positions in Q4 2021 and 11 closed out, a net change of +33 holders.
  • The largest Enanta Pharmaceuticals buyer in Q4 2021 was Invesco, an estimated $14.4M added.
  • The largest Enanta Pharmaceuticals seller in Q4 2021 was Armistice Capital, an estimated $61.2M sold.

Based on aggregated 13F filings for Q4 2021.